As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive ...

As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were ...

The same cell product could potentially be used to treat multiple solid tumors like ovarian, pancreatic and lung cancers.

So far, immune cells that have been engineered to kill cancers, known as CAR T-cells, haven’t worked well against solid ...

GV- and Arch-backed Pelage Pharma is developing a first-of-its-kind topical stem-cell therapy that could redefine the $10B ...

Within the last two decades, multiple stem cell transplants and immunotherapy have been added to intensive chemotherapy as ...

Overall and event-free survival of 100 and 95%, respectively, seen with autologous CD34+ hematopoietic stem-cell lentiviral gene therapy.

The SHARON trial is ongoing and will be expanding to include patients without a BRCA or PALB2 mutation, and General Oncology plans to continue evaluating outcomes and long-term follow-up in this ...

For children born with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), an investigational ...

New research found that gene therapy for children with a form of severe combined immunodeficiency was successful in 95% of ...